糖尿病血管病变的药物治疗进展(3)

来源：网络收集时间：2025-06-15 下载这篇文档手机版

说明：文章内容仅供预览，部分内容可能不全，需要完整文档或者需要复制内容，请下载word后使用。下载word有问题请添加微信号:xuecool-com或QQ：370150219 处理（尽可能给您提供完整文档），感谢您的支持与谅解。

随着人们对糖尿病血管病变发病机制认识的不断深入，其药物治疗方面也在不断地发展，如PARP抑制剂、过氧化亚硝酸盐抑制剂和AGEsI抑制剂等。这为糖尿病血管病变的药物治疗带来了新的希望，同时国内外在治疗糖尿病及其血管病变方面逐渐向微量元素、受体类药物，基因药物、中药活性成分及介入治疗等发展。

【参考文献】
1 Drel VR, Pacher Stevens MJ.et al. Aldose reductase inhibition counteracts nitrosative stress and poly (ADPribose) polymerase activation in diabeticrat kidney and highglucoseexposed human mesangial cells[J]. Free Radic Biol Med , 2006, 40(8): 14541465.

2 Kurono M, Fujii A, Murata M.et al. Slereospecmc recognition of aspirosuccinimide type aldose reductase inhibitor (AS3201) by plasma proteins:a significant role of specific binding by serum albumin in the improved potency and stability[J]. Biochem Pharmacol, 2006, 71 (3):338-353.

3 Misawa S, Kuwabara S, Kanai K.et al. Aldose reductase inhibition alters nodal Na+ currents and nerve conduction in human diabetics[J]. Neurology, 2006, 66(10):1545-1549.

4 Sturm K, Levstik L, DemopoulosⅣ. et al.Permeability characteristics of novel aldose reductase inhibitors using rat junum in vitro[J]. Eur J Pharm Sci, 2006, 28 (1-2):128-133.

5 Wautier M P, Chappey O, Corda S. et al. Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE[J]. Am J Physiol Endocrinol Metab,2001, 280 (5): E685-E94.

6 Kunt T, Forst T, Harzer O.. et al. The influence of advanced glycationend products (AGE)on the expression of human endothelial adhesion molecules[J]. Exp Clin Endocrinol Diabetes, 1998, 106 (3): 183-188.

7Higai K, Shimamura A, Matsumoto K. Amadorimodified glycated albumin predominantly induces Eselectin expression on human umbilical vein endothelial cells through NADPH oxidase activation [J]. Clin Chim Acta,2006,367(1-2):137-143.

8Azal O, Yonem A, Guler S, et al. Efects of aminoguanidine and tolrestat on the development of ocular and renal structural changesin experimental diabetic rats[J]. Diabetes Obes Metab, 2002,4 (1): 75-79.

9Chang Z , Lu Y, Li L, et al. Study on am elioration of aminoguanidine on diabetic neuropathy and its mechanism[J]. ChinPharmacol Bull, 2005, 21(1):103-105.

10 KuoChu C, KwanLih H , ChuenDen T, et al．Aminoguanidine prevents arterial stifening and cardiac hypetrophy in streptozotocininduced diabetes in rats[J]. Br J Pharmacol, 2006, 147(8):944- 950.

11Lin Y T, Tseng Y Z, Chang KC. Aminoguanidine prevents fructoseinduced arterial stiffening in Wistar rats: aortic impedance analysis[J]. Exp Biol Med, 2004, 229(10): 38-45.

12UK Prospective Diabetes Study(UKPDS) Group. Risks of progression of retinopathy and vision loss related to tight blood pressure control in type 2 diabetes mellitus, UKPDS 69. Arch Ophthalmol, 2004,122: 1631-1640.

13周薇薇,王卫庆. 糖尿病视网膜病变的药物治疗进展[J].国际内分泌志杂志，2006, 26: S3.

14黄展华.血管紧张肤转换酶抑制药和糖尿病[J].中国新药与临床杂志, 2003, 22(6): 364-367.

百度搜索“70edu”或“70教育网”即可找到本站免费阅读全部范文。收藏本站方便下次阅读，70教育网，提供经典医药类糖尿病血管病变的药物治疗进展(3)在线全文阅读。

糖尿病血管病变的药物治疗进展(3).doc 将本文的Word文档下载到电脑，方便复制、编辑、收藏和打印下载失败或者文档不完整，请联系客服人员解决！

下载这篇word文档

本文链接：https://www.70edu.com/shiyong/120926.html（转载请注明文章来源）

上一篇：浅谈静脉药物配置中心感染控制的意义
下一篇：重症COPD患者血浆蛋白和肺功能变化及重组生长激素治疗作用